| Home |
About |
Network |
|
info@sandexis.co.uk |
|
||||||||
|
|
||||||||
|
Karl Gibson PhD CChem FRSC |
Publications | |||||||
| Karl
obtained his degree and PhD in Chemistry from the University
of Cambridge. He then spent 5 years as a medicinal chemist
at Merck's Neuroscience Research Centre, working on CNS
targets. In 2002 Karl moved to Pfizer where he has led
medicinal chemistry teams across the Pain, Urology and
Infectious Disease therapeutic areas. As a research project
leader, he has led multi-disciplinary project teams,
delivering candidates to the clinic. His most recent role
was as head of exploratory Pain chemistry where he
specialised in target validation approaches, HTS triage, hit
finding and delivering optimal programs to find clinical
candidates rapidly. He has experience of ion channels,
GPCRs, kinases, enzymes, PPIs and nuclear receptors. He has
managed academic collaborations and large teams of
outsourced chemistry. Outside Pfizer, Karl has taught
medicinal chemistry at Imperial College and Oxford
University and sits on the Biological & Medicinal
Chemistry Section committee of the Royal Society of
Chemistry. |
|||||||||
|
Gavin Whitlock PhD CChem FRSC |
||||||||
| Gavin
obtained his degree and PhD in Chemistry from the University
of Nottingham. He then carried out postdoctoral
research at the University of Oxford and The California
Institute of Technology. Gavin joined Pfizer as a
medicinal chemist in 1997 where over the past 15 years he
has led medicinal chemistry design teams working across
multiple disease areas (Infectious Diseases, Genitourinary,
Tissue Repair, Allergy & Respiratory and Neglected
Diseases) and gene families (kinases, GPCRs,
metalloproteinases and monoamine transporters). This
has resulted in the delivery of 6 candidate molecules to the
clinic. His areas of expertise encompass an
understanding of the molecular properties that are important
for oral, CNS, topical and inhaled routes of administration
and in silico
assessment of toxicology risk to drive low attrition.
Additionally he has experience of leading integrated drug
discovery teams of chemistry, biology, ADME, pharmaceutical
science and drug safety colleagues. |
|||||||||
|
James Mills PhD FRSC |
Publications | |||||||
| James
obtained his degree and PhD in the Pharmacology Department
at the University of Cambridge. His post-doctoral research
was as a part of the TeknoMed project, a collaboration with
Imperial College and Rhone-Poulenc-Rorer in which novel
computational algorithms were applied to the design of
compounds for proprietary projects. He joined Pfizer in 1999
as a Computational Chemist and spent 12 years supporting
over 100 projects across multiple disease areas, writing and
applying novel algorithms to support all stages of the drug
discovery process, including target analysis, HTS triage,
lead and candidate molecule design. His areas of expertise
include SAR analysis and visualisation, virtual screening,
analysis of molecular interactions, ligand superposition and
structure-based drug design. In addition to his role at
Sandexis, James is the founder of Bespoke Comp Chem Ltd. and
a part-time Research Fellow at the Cambridge
Crystallographic Data Centre. |
|||||||||
 |
© Sandexis LLP
2011 Company No. OC368584 Postal address: Innovation House, Discovery Park, Ramsgate Road, Sandwich, Kent, CT13 9ND, UK Business registered address: 45 Queen Street, Deal, Kent, CT14 6EY, UK e-mail: info@sandexis.co.uk |